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ABSTRACT
Background
In chronic HIV infection, antiretroviral therapy–induced normalization of CD4
þ T cell counts
(immune reconstitution [IR]) is associated with a decreased incidence of opportunistic diseases.
However, some individuals remain at risk for opportunistic diseases despite prolonged
normalization of CD4
þ T cell counts. Deficient Epstein-Barr virus (EBV)-specific CD4
þ T cell
function may explain the occurrence of EBV-associated opportunistic malignancy—such as
primary central nervous system (PCNS) lymphoma—despite recovery of absolute CD4
þ T cell
counts.
Methods and Findings
Absolute CD4
þ T cell counts and EBV-specific CD4
þ T cell-dependent interferon-c production
were assessed in six HIV-positive individuals prior to development of PCNS lymphoma
(‘‘cases’’), and these values were compared with those in 16 HIV-infected matched participants
with no sign of EBV-associated pathology (‘‘matched controls’’) and 11 nonmatched HIV-
negative blood donors. Half of the PCNS lymphoma patients fulfilled IR criteria (defined here as
CD4
þ T cell counts  500/ll blood). EBV-specific CD4
þ T cells were assessed 0.5–4.7 y prior to
diagnosis of lymphoma. In 0/6 cases versus 13/16 matched controls an EBV-specific CD4
þT cell
response was detected (p¼0.007; confidence interval for odds ratio [0–0.40]). PCNS lymphoma
patients also differed with regards to this response significantly from HIV-negative blood
donors (p , 0.001, confidence interval for odds ratio [0–0.14]), but there was no evidence for a
difference between HIV-negative participants and the HIV-positive matched controls (p¼0.47).
Conclusions
Irrespective of absolute CD4
þ T cell counts, HIV-positive patients who subsequently
developed PCNS lymphoma lacked EBV-specific CD4
þT cell function. Larger, ideally prospective
studies are needed to confirm these preliminary data, and clarify the impact of pathogen-
specific versus surrogate marker-based assessment of IR on clinical outcome.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org March 2007 | Volume 4 | Issue 3 | e96 0556
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The cardinal feature of HIV infection is depletion of CD4
þ
T cells from the circulation and from lymphoid tissue in most
patients [1,2]. Immunodeﬁciency caused by CD4
þ T cell
depletion is associated with an increased risk for opportun-
istic diseases. The use of antiretroviral therapy (ART) has
dramatically changed the course of HIV infection. ART-
induced immune reconstitution (IR) is reﬂected by the fact
that the incidence of opportunistic infections as well as
several AIDS-deﬁning malignancies decreases with treatment
[3–7]. Speciﬁcally, the incidence of Epstein-Barr virus (EBV)-
associated primary central nervous system (PCNS) lymphoma
has dropped dramatically from 3–8 cases per 1,000 patient-
years to about 1 case per 1,000 patient-years [8,9].
An increase of CD4
þT cell counts to levels  500/ll blood is
used by some to deﬁne complete IR [10]. Among individuals
with sustained IR, opportunistic diseases—including PCNS
lymphoma—pose a particular challenge to both clinicians
and immunologists. We lack controlled data on pathogen-
speciﬁc CD4
þ T cell immunity in patients developing PCNS
lymphoma. Here, the existence of a large cohort of HIV-
infected individuals allowed us to study, in a controlled
setting, predisease virus-speciﬁc CD4
þ T cell function in rare
individuals who developed PCNS lymphoma.
Methods
Study Design
We performed a case-control study within the framework
of the Swiss HIV Cohort Study, by searching the database for
PCNS lymphoma occurring in patients later than 1997. Each
HIV-positive patient who had developed PCNS lymphoma
(‘‘case’’) was matched as available with two or three HIV-
positive patients who had not developed PCNS lymphoma
(‘‘matched controls’’) for: (i) age 6 5 y, (ii) sex, (iii) history of
intravenous drug abuse, (iv) use of ART, (v) time of
documented HIV positivity, (vi) duration of follow-up, and
(vii) the closest available match of median and range of CD4
þ
T cell counts and HIV viral loads (Table 1). In both cases and
matched controls, laboratory data were available every 3–6
mo. An additional control group consisted of 11 nonmatched
HIV-negative individuals (‘‘HIV-negative controls’’). The
study was IRB-approved and conducted according to the
principles expressed in the Helsinki declaration, and written
informed consent was obtained from all participants.
Isolation of Peripheral Blood Mononuclear Cells and
Depletion of CD8
þ T Cells
Peripheral blood mononuclear cells (PBMCs) were pre-
pared by centrifugation through a density gradient on
Histopaque-1077 (Sigma, http://www.sigmaaldrich.com). When
using B cell lysate as the source of antigen, CD8
þ T cells were
depleted using anti-CD8 magnetic beads (Miltenyi Biotech,
http://www.miltenyibiotec.com) following the manufacturer’s
protocol. Depletion was controlled for by FACScan-based
enumeration, and was  98% complete (unpublished data).
Assessment of EBV- and CMV-Specific CD4
þ T Cell-
Dependent Interferon-c Production
Virus-speciﬁc interferon-c (IFN-c) production was deter-
mined by ELISPOT analyses as described [11,12]. Brieﬂy, 96-
well HTS ELISPOT plates from Millipore (http://www.
millipore.com) were precoated overnight with 2 lg/ml of
anti-IFN-c mAb 1-D1K (Mabtech, http://www.mabtech.com),
and washed six times with sterile PBS containing 1% FCS
before use. After washing, 30 ll of R10 culture medium was
added to each well to avoid drying of the membrane, and
100,000 viable cells per well added in 100 ll of R10. The EBV-
speciﬁc CD4
þ T cell response was assessed using as the source
of antigen a set of peptides consisting of 33 HLA II-restricted
optimal epitopes [11,12] and, in CD8
þ T cell-depleted
samples, EBV-infected B cell lysates (Virusys, http://www.
virusys.com) [13]. For each participant at each time point the
highest available SFC measurement (whether from peptide or
B cell lysate assay) is reported. Cytomegalovirus (CMV)-
speciﬁc IFN-c production was assessed using a set of peptides
consisting of 14 HLA II-restricted optimal epitopes (Table
S1). Peptides (all synthesized at Massachusetts General
Hospital, Boston, Massachusetts, United States) were added
at a ﬁnal concentration of 14 lg/ml, B cell lysates at a ﬁnal
concentration of 10 lg/ml. Peptides and B cell lysates were
added in separate wells. The following controls were included
in each experiment: Cells incubated with (i) medium alone,
(ii) with a pool of 91 HLA I-restricted optimal EBV epitopes
(as a functional control for the CD8
þT cell depletion) [11,12],
and (iii) B cell lysate from EBV-naı ¨ve donors (Virusys). PHA
was added at a concentration of 1.8 lg/ml to serve as positive
control. As an additional control we tested an EBV-negative
donor using peptides and (separately) EBV-infected B cell
lysates. In this individual, both methods repeatedly yielded
negative results (unpublished data).
Plates were incubated for 16 h at 37 8C with 5% CO2 before
being developed. After washing with PBS, 100 llo f
biotinylated anti-IFN-c mAb 7-B6–1 (0.5 lg/ml, Mabtech)
was added and plates incubated for 1 h at room temperature.
Plates were washed again and incubated with a 1:2,000
dilution of streptavidin-coupled alkaline phosphatase (Strep-
tavidin-ALP-PQ, Mabtech) for 1 h at room temperature in the
dark. After further washing, IFN-c production was detected as
spots after 10–20 min incubation with nitroblue tetrazolium
and 5-bromo-4-chloro-3-indolyl phosphate (BioRad, http://
www.bio-rad.com). The color reaction was stopped by
washing plates, and plates were air-dried before counting
with an AID ELISPOT Reader Unit (Autoimmun Diagnostika,
http://www.aid-diagnostika.com). Results are expressed as
spot-forming cells (SFC) per million input cells. Thresholds
for positive responses were determined as the mean plus
three standard deviations of negative control wells.
Determination of EBV-Specific Antibody Levels
EBV-VCA, and EBNA1-speciﬁc IgG antibody levels were
determined using commercially available ELISA kits designed
to detect IgG antibody bound to antigen-coated microtiter
plates, following the manufacturer’s protocol (ImmunoWell
IgG test, GenGio, http://www.genbio.com).
CMV Viral Load Determination
Viral DNA quantiﬁcation was performed in serum or
plasma samples using routine TaqMan real-time PCR techni-
que (Applied Biosystems, http://www.appliedbiosystems.com).
Statistical Analysis
If an individual patient’s SFC measurements were 0 at more
than 50% of available time points or, equivalently, if the
PLoS Medicine | www.plosmedicine.org March 2007 | Volume 4 | Issue 3 | e96 0557
CNS Lymphoma and EBV T Cell ResponsesT
a
b
l
e
1
.
P
a
t
i
e
n
t
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
:
C
a
s
e
s
a
n
d
C
o
n
t
r
o
l
s
C
a
s
e
o
r
C
o
n
t
r
o
l
A
g
e
a
,
Y
e
a
r
s
S
e
x
I
V
D
r
u
g
s
A
R
T
H
I
V
P
o
s
i
t
i
v
e
a
,
Y
e
a
r
s
C
D
4
þ
T
C
e
l
l
s
/
l
l
,
M
e
d
i
a
n
(
R
a
n
g
e
)
C
D
8
þ
T
C
e
l
l
s
/
l
l
,
M
e
d
i
a
n
(
R
a
n
g
e
)
H
I
V
V
i
r
a
l
L
o
a
d
(
C
o
p
i
e
s
/
m
l
)
,
M
e
d
i
a
n
(
R
a
n
g
e
)
F
o
l
l
o
w
-
U
p
b
,
Y
e
a
r
s
C
D
4
þ
T
C
e
l
l
A
s
s
e
s
s
m
e
n
t
:
C
o
u
n
t
s
C
D
4
þ
T
C
e
l
l
A
s
s
e
s
s
m
e
n
t
:
F
u
n
c
t
i
o
n
(
E
B
V
)
C
a
s
e
1
3
0
F
N
o
Y
e
s
1
4
6
2
8
(
3
4
2
–
1
,
6
7
3
)
3
,
0
1
8
(
8
5
1
–
9
,
4
4
2
)
5
4
0
(
0
–
9
6
3
,
0
0
0
)
4
.
5
n
¼
1
9
n
¼
7
C
o
n
t
r
o
l
1
3
2
F
N
o
Y
e
s
1
3
5
1
8
(
3
7
2
–
8
9
0
)
1
,
9
8
5
(
1
,
2
5
6
–
2
,
6
5
5
)
1
,
2
0
0
(
0
–
6
9
,
0
0
0
)
5
n
¼
2
2
n
¼
3
C
o
n
t
r
o
l
2
3
0
F
N
o
Y
e
s
n
.
k
.
8
4
4
(
6
2
3
–
1
,
1
5
6
)
1
,
3
4
5
(
1
,
1
0
1
–
1
,
6
7
0
)
1
1
,
1
0
0
(
3
,
0
0
0
–
2
6
,
0
0
0
)
5
n
¼
1
7
n
¼
3
C
o
n
t
r
o
l
3
3
5
F
N
o
Y
e
s
1
6
5
3
9
(
3
2
1
–
6
4
2
)
1
,
0
6
3
(
5
5
0
–
1
,
3
0
8
)
1
3
0
(
0
–
3
8
,
0
0
0
)
5
.
5
n
¼
8
n
¼
3
C
a
s
e
2
4
7
M
N
o
Y
e
s
.
7
6
7
0
(
2
1
0
–
1
,
2
7
0
)
1
,
6
8
5
(
3
4
0
–
3
,
0
2
0
)
7
(
0
–
3
0
0
)
5
n
¼
2
6
n
¼
2
C
o
n
t
r
o
l
4
4
9
M
N
o
Y
e
s
1
7
7
0
7
(
4
0
0
–
1
,
1
7
9
)
1
,
0
5
2
(
6
0
8
–
1
,
3
2
6
)
0
(
0
–
5
,
5
0
0
)
8
n
¼
2
6
n
¼
1
1
C
o
n
t
r
o
l
5
4
9
M
N
o
Y
e
s
2
0
5
8
1
(
3
8
0
–
8
9
4
)
2
,
4
0
2
(
2
,
0
4
6
–
3
,
8
6
9
)
8
0
(
0
–
2
6
,
0
0
0
)
5
.
5
n
¼
1
0
n
¼
3
C
o
n
t
r
o
l
6
4
7
M
N
o
Y
e
s
1
3
6
1
1
(
4
2
3
–
8
7
5
)
1
,
6
4
9
(
1
,
5
0
1
–
2
,
9
1
8
)
5
0
(
0
–
4
4
8
,
0
0
0
)
5
n
¼
2
4
n
¼
3
C
a
s
e
3
5
6
M
N
o
Y
e
s
4
5
6
4
(
2
1
7
–
8
3
3
)
1
,
2
9
1
(
7
0
5
–
1
,
6
7
2
)
1
1
(
0
–
1
0
1
,
0
0
0
)
3
.
5
n
¼
1
3
n
¼
2
C
o
n
t
r
o
l
7
5
9
M
N
o
Y
e
s
8
5
6
3
(
4
0
1
–
6
4
6
)
6
5
6
(
5
0
2
–
7
8
7
)
0
(
0
–
5
,
1
0
0
)
7
.
5
n
¼
1
9
n
¼
1
1
C
o
n
t
r
o
l
8
5
7
M
N
o
Y
e
s
1
5
6
6
2
(
4
3
3
–
7
5
4
)
8
5
8
(
6
9
1
–
1
,
0
2
5
)
0
(
0
–
4
4
)
5
.
2
n
¼
1
1
n
¼
3
C
o
n
t
r
o
l
9
5
6
M
N
o
Y
e
s
1
0
5
9
2
(
4
8
4
–
8
9
6
)
7
6
0
(
4
5
2
–
1
,
2
4
5
)
2
6
(
0
–
1
,
8
0
0
)
6
n
¼
1
9
n
¼
4
C
a
s
e
4
5
0
M
N
o
Y
e
s
1
6
1
6
(
8
–
3
7
3
)
7
2
6
(
2
9
3
–
1
,
8
8
8
)
4
5
5
,
0
0
0
(
1
.
2
3
1
0
1
–
2
.
3
3
1
0
6
)
4
.
5
n
¼
2
6
n
¼
5
C
o
n
t
r
o
l
1
0
5
0
M
N
o
Y
e
s
1
5
8
3
(
3
7
–
1
2
5
)
7
5
2
(
3
7
0
–
1
,
0
5
3
)
8
3
,
0
0
0
(
4
0
0
–
5
7
4
,
0
0
0
)
5
.
5
n
¼
3
3
n
¼
5
C
o
n
t
r
o
l
1
1
4
8
M
Y
e
s
Y
e
s
1
6
8
4
(
1
8
–
1
4
5
)
8
4
6
(
3
5
0
–
1
,
2
1
3
)
1
1
0
(
0
–
4
3
,
0
0
0
)
2
.
5
n
¼
1
1
n
¼
1
C
o
n
t
r
o
l
1
2
4
9
M
N
o
Y
e
s
1
3
1
1
4
(
3
8
–
2
4
6
)
6
1
9
(
3
6
3
–
1
,
2
8
0
)
3
3
0
(
0
–
3
7
0
,
0
0
0
)
4
n
¼
1
7
n
¼
4
C
a
s
e
5
3
6
M
Y
e
s
Y
e
s
5
9
0
(
1
0
–
7
9
0
)
1
,
0
1
0
(
1
2
0
–
2
,
2
9
0
)
3
2
4
,
0
0
0
(
2
.
8
3
1
0
5
–
6
.
6
3
1
0
5
)
4
.
5
n
¼
7
n
¼
2
C
o
n
t
r
o
l
1
3
3
9
M
Y
e
s
Y
e
s
1
0
5
2
(
1
4
–
3
5
0
)
7
4
0
(
4
1
2
–
1
,
4
2
7
)
3
2
,
0
0
0
(
0
–
1
6
5
,
0
0
0
)
4
n
¼
1
1
n
¼
6
C
o
n
t
r
o
l
1
4
3
6
M
N
o
Y
e
s
5
9
0
(
4
0
–
5
3
0
)
1
,
3
5
0
(
4
9
0
–
4
,
5
8
0
)
9
9
,
0
0
0
(
4
4
,
5
0
0
–
1
1
1
,
0
0
0
)
4
.
5
n
¼
1
5
n
¼
3
C
a
s
e
6
4
0
M
N
o
Y
e
s
1
7
7
5
(
2
0
–
1
1
6
)
8
2
5
(
3
6
3
–
2
,
0
1
8
)
3
2
9
,
0
0
0
(
3
.
9
3
1
0
3
–
1
.
2
3
1
0
6
)
5
n
¼
2
0
n
¼
9
C
o
n
t
r
o
l
1
5
4
2
M
N
o
Y
e
s
1
6
8
7
(
4
0
–
1
3
8
)
3
9
2
(
1
3
8
–
9
1
1
)
2
7
5
,
0
0
0
(
2
.
6
3
1
0
3
–
4
.
7
3
1
0
6
)
6
n
¼
1
8
n
¼
1
1
C
o
n
t
r
o
l
1
6
3
9
M
N
o
Y
e
s
n
.
k
.
4
1
(
2
0
–
6
2
)
9
5
9
(
5
3
0
–
2
,
1
1
7
)
1
2
,
4
0
0
(
0
–
2
3
0
,
0
0
0
)
4
.
5
n
¼
1
3
n
¼
4
a
A
g
e
a
n
d
y
e
a
r
s
o
f
d
o
c
u
m
e
n
t
e
d
H
I
V
-
p
o
s
i
t
i
v
i
t
y
a
r
e
g
i
v
e
n
r
e
l
a
t
i
v
e
t
o
t
h
e
l
a
s
t
f
o
l
l
o
w
-
u
p
.
b
F
o
l
l
o
w
-
u
p
(
i
n
y
e
a
r
s
)
p
r
i
o
r
t
o
t
h
e
d
i
a
g
n
o
s
i
s
o
f
P
C
N
S
l
y
m
p
h
o
m
a
i
n
c
a
s
e
s
,
a
n
d
p
r
i
o
r
t
o
t
h
e
l
a
s
t
a
v
a
i
l
a
b
l
e
t
i
m
e
p
o
i
n
t
i
n
c
o
n
t
r
o
l
s
.
n
.
k
.
,
n
o
t
k
n
o
w
n
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
m
e
d
.
0
0
4
0
0
9
6
.
t
0
0
1
PLoS Medicine | www.plosmedicine.org March 2007 | Volume 4 | Issue 3 | e96 0558
CNS Lymphoma and EBV T Cell Responsespatient’s median over all available time points was 0, an EBV-
speciﬁc CD4
þ T cell response was deﬁned as being absent.
Association of ‘‘EBV-speciﬁc T cell response’’ with ‘‘outcome’’
(PCNS lymphoma or not) was examined with an exact Mantel-
Haenszel test of conditional independence. As sensitivity
analysis, the cut-off of 0 SFCs was replaced by 100. Also, the
patient’soutcomewas modelledusing exactconditionallogistic
regression with the logarithm of the patient’s median (or mean)
measurement of the EBV-speciﬁc CD4
þ T cell response (plus 1
to deal with zero-measurements) as a covariate. Samples from
HIV-negative volunteers were nonmatched, and comparisons
were performed with Fisher’s exact test. The Wilcoxon test was
used to quantitatively compare median EBV-speciﬁc CD4
þ T
cell responses in HIV-negative controls with median CD4
þ T
cell responses in HIV-positive matched controls. All statistical
tests were two-sided and performed at the 5% signiﬁcance
level. Statistical analyses were performed with SAS v9.1
software (SAS Institute, http://www.sas.com).
Results
In a search of the Swiss HIV Cohort Study database, six
HIV-positive individuals who developed PCNS lymphoma
were identiﬁed (cases 1–6). Diagnosis was established via
biopsy in cases 1, 2, 3, and 5, and via imaging, detection of
EBV in cerebrospinal ﬂuid, and exclusion of alternate
diagnoses in cases 4 and 6. EBV-speciﬁc antibodies were
detected in all PCNS lymphoma patients more than 2.5 years
prior to diagnosis of lymphoma, and in all matched controls.
The search criteria applied for selection of control patients
are described in the Methods, and patient characteristics are
summarized in Table 1.
Three of the six PCNS lymphoma patients fulﬁlled IR
criteria (cases 1–3) (Figure 1A and Table 1). EBV-speciﬁc
CD4
þ T cell-mediated IFN-c production was assessed cover-
ing a range of 0.5–4.7 y prior to diagnosis of lymphoma. The
n-number of time points at which functional assays were
performed in each patient is listed in Table 1. In 0/6 cases
versus 13/16 matched controls an EBV-speciﬁc CD4
þ T cell-
response was detected (p ¼ 0.007; odds ratio 0, conﬁdence
interval [0–0.40]) (Figure 1B, left and middle). Sensitivity
analyses and exact conditional regressions were also signiﬁ-
cant (p , 0.05 for all analyses). Absolute CD4
þT cell counts in
samples tested from each of the controls were   absolute
CD4
þ T cell counts of samples tested from cases, thus
excluding the possibility that the observed disparities were
driven by differences in CD4
þ T cell counts rather than by
pathogen-speciﬁc CD4
þ T cell function. The maximum SFC
measurement at each available time point for each case and
matched control patient is listed in Table S2, and graphically
presented in Figure S1.
We also assessed the EBV-speciﬁc CD4
þ T cell-mediated
IFN-c production in 11 randomly selected HIV-negative
blood donors (Figure 1B, right). Not surprisingly, PCNS
lymphoma patients also differed in this measurement from
these HIV-negative controls (p , 0.001, odds ratio 0,
conﬁdence interval [0–0.14]). The median EBV-speciﬁc
CD4
þ T cell-response in HIV-positive and HIV-negative
controls was 403 (range 0–905) and 130 (range 40–840),
respectively, and there was no evidence of a difference in
these responses (p ¼ 0.47).
Aiming at distinguishing generally depressed CD4
þ T cell
activity from speciﬁcally decreased anti-EBV responses in the
participants who developed PCNS lymphoma, we tested the
CMV-speciﬁc CD4
þ T cell-response in CMV-positive cases (n
¼ 4), and compared it to CMV-positive controls (n ¼ 4).
Responses were similar, with medians of 540 SFC/10
6 PBMCs
(range 30–1,000 SFC/10
6 PBMCs) and 280 SFC/10
6 PBMCs
(range 55–1,000 SFC/10
6 PBMCs), respectively. In CMV-
negative cases and controls no CMV-speciﬁc CD4
þ T cell
response was detected.
To further test for the speciﬁcity of a possible immune
deﬁcit, CMV viral loads were assessed longitudinally in these
same CMV-positive cases and controls. In each patient four to
11 samples were tested (58 PCR assays in total). CMV DNA
was detected in only two of 29 versus one of 29 samples in
CMV-positive patients versus control participants, respec-
tively. Thus, based on circulating DNA-levels, CMV was well
controlled in both cases and controls.
Discussion
Although PCNS lymphoma can develop in HIV-negative
individuals, it much more often occurs in severely immuno-
Figure 1. Absolute CD4
þ T Cell Counts versus EBV-Specific CD4
þ T Cell
Function
(A) CD4
þ T cell counts from cases 1–6 throughout two years prior to
diagnosis of PCNS lymphoma are shown. Note that in cases 1–3 CD4
þ T
cell counts remained continuously  500/ll.
(B) Ex vivo assessment of EBV-specific CD4
þ T cell-dependent IFN-c
production in HIV-positive patients (cases 1–6) prior to diagnosing PCNS
lymphoma (left), matched control participants (middle), and HIV-
negative healthy controls (right). Median values of the maximum SFC
measurement at each available time point are shown for cases and
matched controls, single SFC values for the HIV-negative nonmatched
study population. Note the lack of EBV-specific CD4
þ T cell activity in
progressors to PCNS lymphoma. In contrast, HIV-infected patients with
no sign of EBV-associated pathology (but a wide range of absolute CD4
þ
T cell counts) did not significantly differ from HIV-negative healthy
control participants.
doi:10.1371/journal.pmed.0040096.g001
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þT cell counts ,50/ll).
Intriguingly, since the introduction of ART, PCNS lymphoma
has also been reported in individuals with CD4
þ T cell counts
over 200/ll or even over 500/ll [14,15].
Here we observed—irrespectively of absolute CD4
þ T cell
counts—an almost complete lack of EBV-speciﬁc CD4
þT cells
in HIV-positive patients who progressed to PCNS lymphoma.
Inversely, even with low CD4
þ T cell counts, EBV-speciﬁc
CD4
þ T cells were detectable in individuals with no sign of
EBV-associated pathology. Similar CMV-speciﬁc CD4
þ T cell
responses and (largely) undetectable CMV replication suggest
that CMV-speciﬁc immunity was adequate in both cases and
controls.
The lack of EBV-speciﬁc CD4
þ T cell function irrespective
of absolute CD4
þ T cell counts likely represents a more
general phenomenon. Case reports and a small case-control
study have reported clinically signiﬁcant CMV and Pneumo-
cystis jiroveci infection in individuals with elevated absolute
CD4
þ T cell counts, and pathogen-speciﬁc CD4
þ T cell
deﬁciency has been suggested to persist in these patients
[16–20]. The fact that seemingly successful ART does not
necessarily allow for the reappearance of pathogen-speciﬁc
CD4
þ T cells is consistent with a recent report showing that
during acute simian immunodeﬁciency virus infection, up to
60% of all CD4
þ T memory cells throughout the body are
irreversibly lost [2]. It thus seems possible that, depending on
the pre-depletion breadth and magnitude of a given
pathogen-speciﬁc immune response, untreated acute HIV
infection has the capacity to remove most (if not all) CD4
þ T
cells with speciﬁcity for a particular pathogen. Such thorough
depletion may then be largely unresponsive to long-term
control of HIV replication by ART and subsequent replenish-
ment of absolute CD4
þ T cell numbers.
Absence of EBV-speciﬁc CD4
þ T cell effector function and/
or help for cytotoxic CD8
þ Tc e l l sm a yp r o v i d ea n
immunological basis for development of PCNS lymphoma
in HIV-infected individuals [21–23]. Larger, ideally prospec-
tive studies are needed to conﬁrm these preliminary data, and
to clarify the impact of pathogen-speciﬁc versus surrogate
marker-based assessment of IR on clinical outcome.
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Figure S1. Ex Vivo Assessment of EBV-Speciﬁc CD4
þ TC e l l -
Dependent IFN-c Production in Positive Patients Prior to Diagnosing
PCNS Lymphoma and in Matched-Control Participants
Shown are progressors (cases) before diagnosis (left) and matched
control participants (right). Each dot represents the maximum SFC
result for a given participant at a given time point. Overlapping dots
are distributed on the x-axis to remain separated.
Found at doi:10.1371/journal.pmed.0040096.sg001 (32 KB PDF).
Table S1. HLA II-Restricted Epitopes Used to Detect CMV-Speciﬁc
CD4
þ T Cells
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Table S2. EBV-Speciﬁc CD4
þ T Cell-Mediated IFN-c Production:
Maximum SFC Values at Each Time Point Tested for Cases and
Matched Controls
Found at doi:10.1371/journal.pmed.0040096.st002 (64 KB PDF).
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Editors’ Summary
Background. AIDS causes disease by inactivating the body’s immune
responses. Most severely affected are the white blood cells known as T
lymphocytes, particularly the CD4
þ T cells that recognize infection and
enable other cells of the immune system to respond. Advanced HIV
infection, marked by very low numbers of CD4
þcells, is associated with a
variety of infections and tumors that are rarely seen in people with intact
immune systems. People with advanced HIV who receive highly active
antiretroviral treatment (HAART) tend to have increases in their CD4
þcell
counts and lose their susceptibility to these so-called opportunistic
infections and cancers. For several common opportunistic infections, it is
considered safe to discontinue preventive antibiotics after a patient’s
total CD4
þ cell count has returned to normal levels on HAART. Some
treated individuals, however, will develop these conditions even after
their CD4
þ cell counts have returned to normal levels. The reason this
happens is unclear.
Why Was This Study Done? For several years, scientists have speculated
that susceptibility to a given opportunistic infection might be due not
simply to low total CD4
þ cells, but to loss of the specific CD4
þ cells that
recognize the infection in question. If this theory is correct, then those
individuals who develop an opportunistic condition after their total CD4
þ
cell counts return to normal might be missing the specific cells that
respond to the microbe causing the condition. The researchers wanted
to test this theory in HIV patients with a brain tumor called primary
central nervous system lymphoma (PCNS lymphoma). The Epstein-Barr
virus (EBV), which causes mononucleosis in the general population, has
been shown to be a cause of PCNS lymphoma in people with AIDS.
What Did the Researchers Do and Find? The researchers studied
patients who developed PCNS lymphoma while enrolled in the Swiss HIV
Cohort, an ongoing study that has enrolled more than 14,000 people. A
large cohort was needed to address this question because PCNS
lymphoma is uncommon, and indeed only six patients with a confirmed
diagnosis were identified. Because they had been followed as part of the
cohort study, these patients had given blood samples that could be
tested in retrospect. Three of these patients had low CD4
þ cell counts
prior to lymphoma diagnosis and three had normal CD4
þcell counts, but
CD4 responses specifically against EBV were absent or very low in all six
patients before they were diagnosed with PCNS lymphoma. The
researchers also studied a comparison group of cohort participants with
comparable CD4
þ cell counts but no PCNS lymphoma, and found that
13/16 of those participants did have CD4 responses to EBV.
What Do These Findings Mean? These results support the idea that the
action of EBV-specific CD4
þ cells, rather than a given level of total CD4
þ
cells, is needed to prevent PCNS lymphoma. Because only a small
number of cases were identified, this must be considered a preliminary
result. Given the rarity of PCNS lymphoma, however, especially in people
receiving HAART, it seems unlikely that a larger cohort will be available in
the near future to provide a more definitive conclusion. Based on this
result, it may be useful to perform similar studies of other opportunistic
infections. If a ‘‘gap’’ in the CD4
þcell response can be shown to increase
the risk of a specific condition, it may become appropriate to test specific
CD4 responses before deciding to discontinue preventive treatment as
CD4
þ cell counts increase on HAART.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040096.
  Read the accompanying Perspective by Mark Jacobson, MD
  The Swiss Cohort Study Web site contains information on related
research projects
  The UCSF Center for HIV Information’s HIV InSite includes resources on
HIV immunology and opportunistic infections
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